Organogenesis Holdings (ORGO) Revenue (2017 - 2026)

Organogenesis Holdings has reported Revenue for 10 years, with the latest figure at $43.8 million in Q2 2026.

• On a quarterly basis, Revenue fell 56.68% year-over-year to $43.8 million in Q2 2026; TTM through Jun 2026 was $457.5 million, a 6.5% increase from a year earlier, with the FY2025 full-year figure at $564.2 million, up 17.04% from the prior year.
• Revenue was $43.8 million for Q2 2026 at Organogenesis Holdings, up from $37.2 million in the prior quarter.
• The five-year high for Revenue was $225.6 million in Q4 2025, with the low at $37.2 million in Q1 2026.
• Average Revenue over 5 years is $111.7 million, with a median of $112.6 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Revenue soared 78.13% in 2025, then plunged 57.06% in 2026.
• Over 5 years, Revenue stood at $115.5 million in 2022, then decreased by 13.73% to $99.7 million in 2023, then climbed by 27.1% to $126.7 million in 2024, then surged by 78.13% to $225.6 million in 2025, then slumped by 80.61% to $43.8 million in 2026.
• The last three Revenue figures came in at $43.8 million (Q2 2026), $37.2 million (Q1 2026), and $225.6 million (Q4 2025), per Business Quant data.